Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with psoriasis had a significantly higher prevalence of autoimmune diseases and other comorbidities compared to individuals without psoriasis.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This study found that overexpression of miR-1246 in peripheral CD4+ T cells can reduce markers associated with inflammation and T cell activation in severe active alopecia areata, suggesting potential therapeutic benefits.

This study found that chronic low-grade inflammation exists independently of excess weight or obesity in women with PCOS, with notable increases in specific cytokines such as IL-9, MCP-3, and MIP-1α.

This study suggests that Notch1 acts as a key signal in skin epithelium, promoting immune cell recruitment and aiding in normal skin repair after damage.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This study found that acne lesions and nonlesional skin in mild-to-moderate acne patients showed significant Th17-skewing and increased antimicrobials, suggesting systemic targets like IL-17/IL-23/IL-36 could be therapeutic.

This study found that IL-17A-producing γδ T cells play a key role in bone fracture healing by promoting bone formation, with deficiencies leading to impaired repair in mice.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This study observed that in aged mouse skin, there was an increase in IL-17-expressing T helper cells, γδ T cells, and innate lymphoid cells, and blocking IL-17 signaling reduced skin inflammation and delayed age-related changes, suggesting it as a potential target to mitigate skin aging.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

In this study using mouse models, researchers found that elevated IL-17a in aged olfactory epithelium impairs olfactory function, while IL-17a inhibition promotes regeneration and mitigates age-related decline.

This study suggests that rather than inhibiting IL-15, selectively stimulating IL-15Ra-mediated signaling could be beneficial for managing alopecia areata and possibly other inflammatory hair loss conditions, as IL-15 promoted hair growth and maintained immune privilege in human hair follicles.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This study found that CXCL12+ fibroblast subsets in mouse skin play a critical role in recruiting neutrophils and defending against S. aureus infection, with similar fibroblast activity observed in human psoriatic skin.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

This study found that γδ T cells play a role in regulating stromal behavior, influencing the composition and vascularity of fibrotic tissues during the foreign body response.

This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.

This study found that feeding aged mice a probiotic yogurt induced changes leading to thicker, healthier fur, suggesting a bacteria-triggered interleukin-10-dependent mechanism that mimics signs of youth and reproductive fitness.